Clinical Trial Results:
A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism. RE-MEDY
Summary
|
|
EudraCT number |
2005-002536-94 |
Trial protocol |
FI AT SE CZ BE SK GB ES DE HU PT GR DK IT BG |
Global completion date |
08 Oct 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 May 2016
|
First version publication date |
22 Mar 2015
|
Other versions |
|
Summary report(s) |
1160.47 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.